Whole transcriptome gene expression in Alzheimer's disease (AD) patients [lncRNA]

Alzheimer disease (AD) is the most common type of dementia. It is a progressive disease initially characterized by memory loss and leading to loss of the ability to respond to the environment. Currently, there is no single molecular or imaging test that can establish an AD diagnosis. A clinical diagnosis is often the results of multiple cognitive tests, spinal fluid or other bodily fluid tests for specific biomarkers and brain imaging, and it is often a diagnosis of exclusion for other diseases. We utilized a whole transcriptome sequencing approach to analyze gene expression in AD patients and control subjects blood samples with the goal of developing a novel panel of biomarkers for the disease. Whole blood sample were collected from 50 AD patients and 50 matched controls. AD patients were defined by a clinical diagnosis supported by 3 cognitive tests (MMSE, ADAS, CDR). Healthy donors have an unremarkable clinical history and their scores in the 3 cognitive tests are within normal ranges.